Ruminant Feed Ban Support Project; Availability of Cooperative Agreements: Request for Applications: RFA-FDA-ORA-05-3; Catalog of Federal Domestic Assistance Number: 93.449, 38177-38182 [05-13114]
Download as PDF
Federal Register / Vol. 70, No. 126 / Friday, July 1, 2005 / Notices
Approved But Unfunded Applications
Applications that are approved but
unfunded may be held over for funding
in the next funding cycle, pending the
availability of funds, for a period not to
exceed one year.
3. Anticipated Announcement and
Award Dates
Subject to the availability of funding,
ADD intends to award new grants
resulting from this Program
Announcement during the fourth
quarter of Fiscal Year 2005. Up to
$350,000 in Federal funds will be
available to support these projects this
fiscal year.
For the purpose of the awards under
this Program Announcement, the
successful applicants should expect a
project start date of September 1, 2005.
VI. Award Administration Information
1. Award Notices
The successful applicants will be
notified through the issuance of a
Financial Assistance Award document
which sets forth the amount of funds
granted, the terms and conditions of the
grant, the effective date of the grant, the
budget period for which initial support
will be given, the non-Federal share to
be provided, and the total project period
for which support is contemplated. The
Financial Assistance Award will be
signed by the Grants Officer and
transmitted via postal mail.
Organizations whose applications will
not be funded will be notified in
writing.
2. Administrative and National Policy
Requirements
Grantees are subject to the
requirements in 45 CFR part 74 (nongovernmental) or 45 CFR part 92
(governmental).
Direct Federal grants, sub-award
funds, or contracts under this Family
Support Initiative 2005 program shall
not be used to support inherently
religious activities such as religious
instruction, worship, or proselytization.
Therefore, organizations must take steps
to separate, in time or location, their
inherently religious activities from the
services funded under this Program.
Regulations pertaining to the Equal
Treatment For Faith-Based
Organizations, which includes the
prohibition against Federal funding of
inherently religious activities, can be
found at either 45 CFR part 87.1 or the
HHS Web site at https://
www.os.dhhs.gov/fbci/waisgate21.pdf.
Financial Reports: Semi-Annually.
Grantees will be required to submit
program progress and financial reports
(SF–269) throughout the project period.
Program progress and financial reports
are due 30 days after the reporting
period. In addition, final programmatic
and financial reports are due 90 days
after the close of the project period.
VII. Agency Contacts
Program Office Contact: Joan Rucker,
Program Specialist, U.S. Department of
Health and Human Services,
Administration for Children and
Families, Administration on
Developmental Disabilities, 370
L’Enfant Promenade, SW., Mail Stop
405–D, Washington, DC 20447. Phone:
202/690–7898. Fax: 202/205–8037. Email: jrucker@acf.hhs.gov.
Grants Management Office Contact:
Tim Chappelle, Grants Officer, U.S.
Department of Health and Human
Services, Administration for Children
and Families, Administration on
Developmental Disabilities, 370
L’Enfant Promenade, SW., 8th Floor,
Washington, DC 20447. Phone: 202/
401–4855. Fax: 202/401–5468. E-mail:
tichappelle@acf.hhs.gov.
VIII. Other Information
All forms are available online at:
https://www.acf.hhs.gov/programs/ofs/
forms/htm.
Notice: Beginning with FY 2006, the
Administration for Children and
Families (ACF) will no longer publish
grant announcements in the Federal
Register. Beginning October 1, 2005,
applicants will be able to find a
synopsis of all ACF grant opportunities
and apply electronically for
opportunities via: www.Grants.gov.
Applicants will also be able to find the
complete text of all ACF grant
announcements on the ACF Web site
located at: https://www.acf.hhs.gov/
grants/.
Please reference Section IV.3 for
details about acknowledgement of
received applications.
Dated: June 24, 2005.
Patricia A. Morrissey,
Commissioner, Administration on
Developmental Disabilities.
[FR Doc. 05–13096 Filed 6–30–05; 8:45 am]
BILLING CODE 4184–01–P
3. Reporting Requirements
Programmatic Reports: Quarterly.
VerDate jul<14>2003
18:11 Jun 30, 2005
Jkt 205001
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
38177
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Ruminant Feed Ban Support Project;
Availability of Cooperative
Agreements: Request for Applications:
RFA–FDA–ORA–05–3; Catalog of
Federal Domestic Assistance Number:
93.449
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
I. Funding Opportunity Description
The Food and Drug Administration
(FDA), Office of Regulatory Affairs
(ORA), Division of Federal-State
Relations (DFSR) in coordination with
the Center for Veterinary Medicine
(CVM), is announcing the availability of
cooperative agreements to further
enhance the infrastructure of State,
territorial, and tribal animal feed safety
and bovine spongiform encephalopathy
(BSE) prevention programs. These
cooperative agreements are intended to
fund additional personnel, equipment,
supplies and training to support
activities related to the FDA ruminant
feed ban (21 CFR part 589.2000)
(referred to as the ruminant feed ban),
in State, territory, and tribal
governments.
Under these cooperative agreements,
the State, territory, and tribal
governments would enhance their feed/
BSE safety programs to increase the
ability to locate and visit firms involved
in the manufacture, distribution, and
transportation of animal feed and
operations feeding ruminant animals in
their jurisdiction, to verify compliance
with the ruminant feed ban. Funds
could be used to increase State,
territory, and tribal personnel dedicated
to conducting these inspections. Funds
could also be used for supplies, training,
and laboratory equipment for feed
sample testing using FDA validated
methods. The goal of enhancing their
feed/BSE safety programs is to increase
State, territory, and tribal inspections
under section 702 of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act)
(21 U.S.C. 372) of renderers, protein
blenders, and feed mills that
manufacture animal feeds and feed
ingredients, and inspections of salvagers
of food and feed, and transporters of
animal feed and feed ingredients
utilizing materials prohibited under the
ruminant feed ban. Finally, the Feed
Ban Support Project funds are intended
to supplement, not replace, State
funding for program improvement.
E:\FR\FM\01JYN1.SGM
01JYN1
38178
Federal Register / Vol. 70, No. 126 / Friday, July 1, 2005 / Notices
There are seven key project areas
identified for this effort:
• Hire and/or train State/territory/
tribal personnel to conduct ruminant
feed ban inspections. Training of State/
territory/tribal personnel may be
accomplished through the ORA
University, or the Association of
American Feed Control Officials Annual
Feed Seminar, or other training that
meets State/territory/tribal and FDA
requirements. New hires for this
program must meet the State/territory/
tribal agency’s qualifications for feed
inspections and sampling techniques.
• Hire and/or train laboratory
personnel to verify that feed samples are
free of materials prohibited under the
ruminant feed ban. Laboratory analyses
must utilize FDA methodologies for
detection of prohibited materials.
• Identify and inspect renderers,
protein blenders, commercial animal
feed manufacturers, distributors
(including retailers), transporters of
animal feed and feed ingredients, onfarm animal feed mixers, and ruminant
feeders within the State/territory/tribal
jurisdiction. These inspections would
be conducted under section 702 of the
FD&C Act using and completing the
FDA Ruminant Feed Ban Inspection
Checklist and Ruminant Feed Ban
Compliance Program to verify
compliance with the ruminant feed ban.
These inspections would be conducted
by officers and employees duly
commissioned by FDA in accordance
with section 702 of the FD&C Act.
• Conduct surveillance sampling of
renderers, protein blenders, and feed
mills that manufacture with materials
prohibited under the ruminant feed ban.
A minimum of one sample from each
facility would be obtained during the
inspection and would be analyzed by
the State/territorial/tribal government
for prohibited materials. This
surveillance sampling would be
conducted under section 702 of the
FD&C Act using and completing the
FDA Ruminant Feed Ban Inspection
Checklist and Ruminant Feed Ban
Compliance Program to verify
compliance with the ruminant feed ban.
This surveillance sampling would be
conducted by officers and employees
duly commissioned by FDA in
accordance with section 702 of the
FD&C Act.
• Locate and inspect other firms of
specified concern, such as feed
salvagers, feed transporters, and
ruminant feeders. These inspections
would be conducted under section 702
of the FD&C Act using and completing
the FDA Ruminant Feed Ban Inspection
Checklist and Ruminant Feed Ban
Compliance Program to verify
VerDate jul<14>2003
18:11 Jun 30, 2005
Jkt 205001
compliance with the ruminant feed ban.
These inspections would be conducted
by officers and employees duly
commissioned by FDA in accordance
with section 702 of the FD&C Act.
• Provide copies of all completed BSE
checklists and sample results as a part
of the quarterly program progress report
to the FDA Project officer or designated
office, as well as provide completed
checklists and sample results in
accordance with section 702 of the
FD&C Act.
• Be able to identify and quantify
improvements to the existing State/
territory/tribal BSE program or
developing new programs (i.e.,
personnel hiring, personnel training,
equipment upgrades, increase in
inspections conducted) in the quarterly
reports as a result of the cooperative
agreement.
FDA will support the projects covered
by this notice under the authority of
Section 311 of the Public Health
Security and Bioterrorism Preparedness
and Response Act of 2002 (the
Bioterrorism Act) (Public Law 107–188),
which amends the FD&C Act by adding
section 909 (21 U.S.C. 399). FDA’s
research program is described in the
Catalog of Federal Domestic Assistance,
No. 93.449.
territorial/tribal governments for them
to develop new or enhance the
capability of their existing Feed/BSE
programs and assist in an increased
surveillance presence throughout the
commercial feed channels to prevent the
introduction or amplification of BSE in
the United States. State/territorial/tribal
inspections are based on a
determination of compliance of firms
with the ‘‘Animal Proteins Prohibited In
Ruminant Feeds’’ regulation, (21 CFR
589.2000), as well as any subsequent
regulations and guidance applicable to
the BSE ruminant feed ban. This
regulation is designed to prevent the
establishment and amplification of BSE
through animal feed, by prohibiting the
use of certain proteins derived from
mammalian tissue in the feeding of
ruminant animals. The regulation affects
renderers, protein blenders, commercial
animal feed manufacturers, distributors
(including retailers), transporters of
animal feed and feed ingredients, onfarm animal feed mixers, and ruminant
feeders. Based on the need to control the
entry and spread of this disease, the
agency has set a goal to assist in the
development of new or the
enhancement of existing State/territory/
tribal BSE programs to help meet
compliance with the regulation.
1. Background
The events of September 11, 2001,
reinforced the need to enhance the
security and safety of the U.S. food
supply. Congress responded by passing
the Bioterrorism Act which President
Bush signed into law on June 12, 2002.
The Bioterrorism Act is divided into the
following five titles:
• Title I—National Preparedness for
Bioterrorism and Other Public Health
Emergencies
• Title II—Enhancing Controls on
Dangerous Biological Agents and Toxins
• Title III—Protecting Safety and
Security of Food and Drug Supply
• Title IV—Drinking Water Security
and Safety
• Title V—Additional Provisions
Subtitle A of Title III—Protection of
Food Supply, Section 311—Grants to
States for Inspections, amends the FD&C
Act by adding section 909 to authorize
the Secretary of Health and Human
Services to award grants to States,
territories, and Indian tribes that
undertake examinations, inspections,
and investigations, and related activities
under section 702 of the FD&C Act. The
grant funds are only available for the
costs of conducting these examinations,
inspections, investigations, and related
activities.
Toward these ends, ORA is offering
these cooperative agreements to State/
2. Program Goals
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
The goal of FDA’s ORA Cooperative
Agreement Program is to enhance,
complement, develop and improve
State/territory/tribal feed safety and
surveillance programs. This will be
accomplished through the provision of
funding for additional equipment,
supplies, funding for personnel, training
in current FDA approved feed testing
methodologies, participation in
proficiency testing to establish
additional reliable laboratory sample
analysis capacity, and analysis of
surveillance samples and State/
territorial/tribal compliance inspections.
This will also require extensive
cooperation and coordination with FDA
District Offices to minimize duplication
of inspections.
II. Award Information
1. Award Instrument
Support will be in the form of a
cooperative agreement. Substantive
involvement by the awarding agency is
inherent in the cooperative agreement
award. Accordingly, FDA will have
substantial involvement in the program
activities of the project funded by the
cooperative agreement.
Substantive involvement includes,
but is not limited to, the following:
E:\FR\FM\01JYN1.SGM
01JYN1
Federal Register / Vol. 70, No. 126 / Friday, July 1, 2005 / Notices
• FDA assistance and coordination in
the sharing of information on the
identification and location of all
renderers, protein blenders, commercial
animal feed manufacturers, distributors
(including retailers), transporters of
animal feed and feed ingredients, onfarm animal feed mixers, and ruminant
feeders known to FDA and the State/
territorial/tribal agency.
• FDA assistance in the training of
State/territorial/tribal BSE program
personnel.
• FDA assistance in the training of
State/territorial/tribal laboratory
personnel to verify that feed samples are
free of materials prohibited under the
ruminant feed ban.
• FDA assistance in the surveillance
sampling of renderers, protein blenders,
and feed mills that manufacture with
materials prohibited under the ruminant
feed ban.
• FDA assistance and cooperation in
the location and inspection of other
firms of specified concern, such as feed
salvagers, feed transporters, and
ruminant feeders.
• FDA will assist in the review of all
completed checklists and sample results
provided as a part of the quarterly
reports.
• FDA will assist with joint
inspections for training, compliance,
auditing or other field activities as
requested by the awardee.
2. Applicability
All cooperative agreement projects
that are developed at State, territorial,
and tribal levels must have existing BSE
feed safety and surveillance programs or
propose in detail the development of a
State/territory/tribal feed/BSE
regulatory program.
3. Award Amount
The total amount of funding available
in Fiscal Year (FY) 2005 is $2 million.
Cooperative agreements will be awarded
up to $250,000 in total (direct plus
indirect) costs per year for up to three
(3) years and can be modified for years
2 and 3, depending on the availability
of funds and review of prior year’s
accomplishments.
4. Length of Support
The length of support will depend on
the nature of the project. For those
projects with an expected duration of
more than 1 year, a second or third year
of noncompetitive continuation of
support will depend on the following
factors: (1) Performance during the
preceding year and (2) availability of
Federal funds.
VerDate jul<14>2003
18:11 Jun 30, 2005
Jkt 205001
2. Cost Sharing or Matching
5. Funding Plan
It is anticipated that FDA will make
up to ten awards in FY 2005. The
number of projects funded will depend
on the quality of the applications
received and is subject to availability of
Federal funds to support the projects.
In addition, if a cooperative
agreement is awarded, grantees will be
informed if any additional
documentation should be needed to
support their award. Funds may be
requested in the budget to travel to FDA
for meetings with program staff about
the progress of the project. The project
office will have continuous interaction
with the grantee through inspection
field audits, collection of quarterly
progress reports, and provision of
training, joint inspections, and
compliance. There may be other regular
meetings with grantees to assist in
fulfilling the requirements of the
cooperative agreement.
These cooperative agreements will be
made to either fund the development of
new State/territory/tribal BSE programs
or to enhance existing State/territory/
tribal BSE programs for the funding of
items such as: Supplies, lab equipment,
surveillance, sample collection,
personnel, for the provision of training
in current inspectional and analytical
methodology, for the analysis of feed
and feed products, and ruminant feed
ban inspections. Successful applications
will be selected for funding to ensure a
broad geographic distribution of the
program. Size of the existing or new
State/territory/tribal program and
number of facilities to be covered under
the cooperative agreement will also be
a determining factor.
States with current BSE/ruminant
feed ban contracts from FDA can
maintain these contracts for feed/BSE
inspections at the discretion of the State
and FDA. However, the facilities and
work covered under the contract cannot
be counted towards fulfillment of the
cooperative agreement and must remain
distinct and separate from the
cooperative agreement. These
cooperative agreements are not to fund
licensed medicated feed or routine feed
safety good manufacturing practice
(GMP) inspections that are unrelated to
the ruminant feed ban.
III. Eligibility Information
1. Eligible Applicants
This cooperative agreement program
is only available to State, territory, and
tribal agency feed/BSE regulatory
programs that undertake inspections
and related activities under section 702
of the FD&C Act.
PO 00000
Frm 00090
Fmt 4703
38179
Sfmt 4703
Cost sharing is not required.
3. Other
Dun and Bradstreet Number (DUNS).
As of October 1, 2003, applicants are
required to have a DUNS number to
apply for a grant or cooperative
agreement from the Federal
Government. The DUNS number is a 9digit identification number that
uniquely identifies business entities.
Obtaining a DUNS number is easy and
there is no charge. To obtain a DUNS
number, call 1–866–705–5711. Be
certain that you identify yourself as a
Federal grant applicant when you
contact Dun and Bradstreet.
IV. Application and Submission
1. Addresses to Request Application
FDA is accepting new applications for
this program electronically via
Grants.gov. Applicants are strongly
encouraged to apply electronically by
visiting the Web site https://
www.grants.gov and following
instructions under ‘‘APPLY.’’ The
required application PHS 424, which is
part of the PHS 5161–1 form, can be
completed and submitted online. The
package should be labeled ‘‘Response to
RFA–FDA–ORA–05–3.’’ If you
experience technical difficulties with
your online submission you should
contact either Cynthia Polit, Grants
Management Specialist, Division of
Contracts and Grants Management
(HFA–500), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–7180, email: cpolit@oc.fda.gov or the
Grants.gov Customer Response Center
for assistance.
To comply with the President’s
Management Agenda, the Department of
Health and Human Services is
participating as a partner in the new
governmentwide Grants.gov Apply site.
Users of Grants.gov will be able to
download a copy of the application
package, complete it offline, and then
upload and submit the application via
the Grants.gov site. We request your
participation in the Grants.gov project.
When you enter the Grants.gov site, you
will find information about submitting
an application electronically through
the site.
In order to apply electronically, the
applicant must have a DUNS number
and register in the Central Contractor
Registration (CCR) database as described
in section IV.6.A of this document.
E:\FR\FM\01JYN1.SGM
01JYN1
38180
Federal Register / Vol. 70, No. 126 / Friday, July 1, 2005 / Notices
2. Content and Form of Application
A. General Information
The applicant will be judged on, and
must specifically address, the following
in the cooperative agreement
application:
• Demonstrate the availability of
adequately trained BSE program staff
and/or the criteria to hire and/or train
personnel to conduct ruminant feed ban
inspections.
• Demonstrate the availability of
adequately trained laboratory personnel
and the criteria to hire and/or train
laboratory personnel to verify that feed
samples are free of materials prohibited
under the ruminant feed ban. Verify that
laboratory analyses will utilize FDA
approved tests and methodologies for
detection of prohibited materials.
• Provide a detailed description of
current feed regulatory program or
proposal to develop a feed regulatory
program, including types of inspections
performed, and types and numbers of
feed establishments in the State/
territorial/tribal inventory.
• Provide a properly detailed budget
that is intended to develop or enhance
the BSE program in the State/territory/
tribe.
• Provide an accurate count of all
feed facilities including renderers,
protein blenders, commercial animal
feed manufacturers, distributors
(including retailers), transporters of
animal feed and feed ingredients, onfarm animal feed mixers, and ruminant
feeders in their State, territory, or tribal
government. Provide an indication of
how many of each of these facilities
would be covered each year under this
agreement.
• Provide a detailed description of
how the BSE program inspections and/
or feed sampling and analyses are to be
performed.
• Provide detailed descriptions on
how current, noninspected facilities
and/or nonidentified facilities will be
identified and added to the State’s
inspection responsibilities.
• Demonstrate the ability to satisfy
the reporting requirements outlined in
section VI.3.A of this notice.
• Provide current funding level
certification for their existing BSE
program from State/territory/tribal
funding appropriations.
• Outline detailed methodology for
program improvement or program
development to accomplish the work.
• Provide justification for hiring new
staff, hiring qualifications, their training
needs and any new equipment.
• Provide a clearly detailed
description how the State/territory/tribe
BSE program will follow the procedures
VerDate jul<14>2003
18:11 Jun 30, 2005
Jkt 205001
set forth in section 702 of the FD&C Act
for notifying FDA of violative facilities
for enforcement under FDA jurisdiction.
B. Laboratory Facilities
The applicant must provide a
complete description of the facilities,
including the following information:
The name and address of the State/
territory/tribal facility conducting the
BSE testing; the name of the most
responsible individual for the facility
where the testing will be conducted;
and, the location and installation
requirements of any equipment
purchased with cooperative agreement
funds.
Other facilities information that must
be provided includes:
• Operational support areas to be
used for the project, including details
about the availability of ancillary
laboratory safety and support equipment
and facilities;
• Details describing the sample
receiving and sample storage areas and
a description of any existing chain-ofcustody procedures;
• A detailed description of the
proposed upgrades to existing
laboratory facilities to accommodate
new equipment including drawings and
cost estimates.
Laboratory Management Practices:
For the laboratory, the following
management information must be
provided:
• A summary description of any
quality management system defined, in
development, or in place as it relates to
quality control and quality assurance
procedures and practices;
• A summary description of staffing
management, specifically to include
BSE testing abilities and procedures;
• A summary description of
procedures in place to monitor BSE
sample workflow, including the tracking
and monitoring of sample analyses in
progress to include a description of the
laboratory work product review process.
Additionally, the ability to perform and
complete the BSE analyses and provide
a report of a sample analysis within a
responsive and reasonable timeframe
must be described. At a minimum, the
grantee shall utilize and follow the
laboratory testing procedures,
methodology, and protocol employed
and approved by FDA in the testing of
all BSE samples to ensure compliance
with the ruminant feed ban.
In addition, if a cooperative
agreement is awarded, grantees will be
informed if any additional
documentation should be needed to
support their award.
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
C. Format for Application
Data and information included in the
application will generally not be
publicly available prior to the funding
of the application. After funding has
been granted, data and information
included in the application will be
given confidential treatment to the
extent permitted by the Freedom of
Information Act (5 U.S.C. 552(b)(4)) and
FDA’s implementing regulations
(including 21 CFR 20.61, 20.105, and
20.106). By accepting funding, the
applicant agrees to allow FDA to
publish specific information about the
cooperative agreement.
Information collection requirements
requested on Form PHS 5161–1 (Rev. 7/
00) have been sent by PHS to the Office
of Management and Budget (OMB) and
have been approved and assigned OMB
control number 0348–0043.
3. Submission Dates and Times
For FY 05, the application receipt
date is August 15, 2005.
Applications will be accepted from 8
a.m. to 4:30 p.m., Monday through
Friday, until the established receipt
date. Please do not send applications to
the Center for Scientific Review (CSR) at
the National Institutes of Health (NIH).
Any application sent to NIH/CSR that is
forwarded to the FDA Grants
Management Office and not received in
time for orderly processing will be
judged nonresponsive and returned to
the applicant.
Applications submitted electronically
must be received by the close of
business on the established receipt date.
No addendum material will be
accepted after the established receipt
date.
4. Intergovernmental Review
The regulations issued under
Executive Order 12372,
Intergovernmental Review of Federal
Programs (45 CFR part 100) apply.
Applicants (other than federally
recognized Indian Tribal governments)
should contact the State’s Single Point
of Contact (SPOC) as early as possible to
alert the SPOC to the prospective
application(s) and to receive any
necessary instructions on the State’s
review process. A current listing of
SPOCs is located at: http//
www.whitehouse.gov/omb/grants/
spoc.htlm. The SPOC should send any
State review process recommendations
to the FDA administrative contact (see
AGENCY CONTACTS in section VII of this
document). The due date for the State
process recommendations is no later
than 60 days after the deadline date for
the receipt of applications. FDA does
E:\FR\FM\01JYN1.SGM
01JYN1
Federal Register / Vol. 70, No. 126 / Friday, July 1, 2005 / Notices
not guarantee to accommodate or
explain SPOC comments that are
received after the 60-day cutoff.
5. Funding Restrictions
These cooperative agreements are not
to fund licensed medicated feed or
routine feed safety GMP inspections that
are unrelated to the ruminant feed ban.
These awards may be only used for the
development of new State/territory/
tribal BSE programs or to enhance and
supplement existing State/territory/
tribal BSE program funding. States with
current BSE/ruminant feed ban
contracts from FDA can maintain these
contracts for feed/BSE inspections at the
discretion of the State and FDA.
However, the facilities and work
covered under the contract cannot be
counted towards fulfillment of the
cooperative agreement and must remain
distinct and separate from the
cooperative agreement.
6. Other Submission Requirements
A. Central Contractor Registration
In anticipation of the https://
www.grants.gov electronic application
process, applicants must register with
the CCR database. This database is a
governmentwide warehouse of
commercial and financial information
for all organizations conducting
business with the Federal Government.
Registration with CCR will eventually
become a requirement and is consistent
with the governmentwide management
reform to create a citizen-centered web
presence and build e-gov infrastructures
in and across agencies to establish a
‘‘single face to industry.’’ The preferred
method for completing a registration is
through the World Wide Web at http:/
/www.ccr.gov. This Web site provides a
CCR handbook with detailed
information on data you will need prior
to beginning the online pre-registration,
as well as steps to walk you through the
registration process. You must have a
DUNS number to begin your
registration.
In order to access https://grants.gov an
applicant will be required to register
with the Credential Provider.
Information about this is available at
https://www.grant.gov/
CredentialProvider.
B. Copyright Material
Applicants and applicants’ subgrantees and sub-contractors must
ensure compliance that any projects
developed in whole or in part with
Federal funds may be made available to
other State, territorial, local, and tribal
feed/BSE regulatory agencies by FDA or
its agents. Any copyrighted or
VerDate jul<14>2003
18:11 Jun 30, 2005
Jkt 205001
copyrightable works shall be subject to
a royalty-free, nonexclusive, and
irrevocable license to the Federal
Government to reproduce, publish, or
otherwise use them, and to authorize
others to do so for Federal Government
purposes.
V. Application Review Information
1. Criteria
A. General Information
FDA grants management and program
staff will review all applications sent in
response to this notice. To be
responsive, an application must be
submitted in accordance with the
requirements of this notice and must
bear the original signature of the
applicant institution’s/organization’s
authorized official. Applications found
to be nonresponsive will be returned to
the applicant without further
consideration. Applicants are strongly
encouraged to contact FDA to resolve
any questions about criteria before
submitting their application. Please
direct all questions of a technical or
scientific nature to the ORA program
staff and all questions of an
administrative or financial nature to the
grants management staff (see AGENCY
CONTACTS in section VII of this
document).
The original signature requirement
does not apply to applications
submitted electronically.
B. Scientific/Technical Review Criteria
Applications will be considered for
funding on the basis of their overall
technical merit as determined through
the review process. Program criteria will
include availability of funds and overall
program balance in terms of geography
and with respect to existing inventory of
feed firms within their State.
The ad hoc expert panel will review
applications based on the ‘‘Content and
Form of Application’’ requirements
listed in section IV.2.A of this
document.
A score will be assigned based on the
scientific/technical review criteria. The
review panel may advise the program
staff about the appropriateness of the
proposal to the goals of this ORA/Office
of Regional Operations (ORO)/DFSR and
CVM cooperative agreement program.
C. Program Review Criteria
Applications will be considered for
funding on the basis of their overall
technical merit as determined through
the review process. Program criteria will
include availability of funds and overall
program balance in terms of geography
with respect to existing and projected
awards.
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
38181
2. Review and Selection Process
Responsive applications will be
reviewed and evaluated for scientific
and technical merit by an ad hoc panel
of experts in the subject field of the
specific application. Final funding
decisions will be made by the
Commissioner of Food and Drugs or his
designee.
3. Anticipated Announcement and
Award
Notification regarding the results of
the review is anticipated by September
1, 2005. The expected start date for the
FY 05 awards will be September 29,
2005.
VI. Award Administration Information
1. Award Notices
The FDA Grants Management Office
will notify applicants who have been
selected for an award. Awards will
either be issued on a Notice of Grant
Award (PHS 5152) signed by the FDA
Chief Grants Management Officer and be
sent to successful applicants by mail or
be transmitted electronically.
2. Administrative and National Policy
Requirements
These agreements will be subject to
all applicable policies and requirements
that govern the grant programs of PHS,
including 45 CFR part 92 and the PHS
Grants Policy Statement.
Equipment purchased under this
cooperative agreement is subject to the
requirements of 45 CFR part 92.31,
‘‘Real property.’’
Applicants must adhere to the
requirements of this Notice. Special
Terms and Conditions regarding FDA
regulatory requirements and adequate
progress of the study may be part of the
awards notice.
PHS strongly encourages all
cooperative agreement recipients to
provide a smoke-free workplace and to
discourage the use of all tobacco
products. This is consistent with the
PHS mission to protect and advance the
physical and mental health of the
American people.
FDA is committed to achieving the
health promotion and disease
prevention objectives of ‘‘Healthy
People 2010,’’ a national effort designed
to reduce morbidity and mortality and
to improve quality of life. Applicants
may obtain a paper copy of the ‘‘Healthy
People 2010’’ objectives, vols. I and II,
for $70 ($87.50 foreign) S/N 017–000–
00550–9, by writing to the
Superintendent of Documents, P.O. Box
371954, Pittsburgh, PA 15250–7954.
Telephone orders can be placed to 202–
512–2250. The document is also
E:\FR\FM\01JYN1.SGM
01JYN1
38182
Federal Register / Vol. 70, No. 126 / Friday, July 1, 2005 / Notices
available in CD–ROM format, S/N 017–
001–00549–5 for $19 ($23.50 foreign) as
well as on the Internet at https://
www.healthypeople.gov/. (FDA has
verified the Web site address, but we are
not responsible for subsequent changes
to the Web site after this document
publishes in the Federal Register.)
Internet viewers should proceed to
‘‘Publications.’’
3. Reporting
A. Reporting Requirements
The original and two copies of the
annual Financial Status Report (FSR)
(SF–269) must be sent to FDA’s grants
management officer within 90 days of
the budget period end date of the grant.
For continuing cooperative agreements,
an annual program progress report is
also required. For such cooperative
agreements, the noncompeting
continuation application (PHS 5161–1)
will be considered the annual program
progress report.
Quarterly progress reports as well as
a final program progress report are
required. Quarterly progress reports
must contain, but are not limited to the
following:
1. Status report on the installation and
operational readiness of any analytical
equipment that is purchased.
2. Status report on the hiring and
training of State/territorial/tribal
laboratory personnel.
3. Copies of the inspection report on
the firms for which Ruminant Feed Ban
Inspection checklists were completed
including general assessment of
compliance status.
4. Summary report on the facility
inventory that is maintained in the
State/territory/tribal government.
5. Status report on the hiring and
training of personnel to conduct the
inspections.
6. Report on feed sample descriptions
and subsequent analytical results.
7. Where the examinations,
inspections, or investigations and
related activities undertaken under
section 702 of the FD&C Act result in a
State/territorial/tribal enforcement
action, a summary report of the
followup actions and final resolution of
the findings.
8. Summary of improvements
(identify and quantify) in the overall
State/territory/tribal BSE program
resulting from the cooperative
agreement.
9. Provide copies of all completed
BSE checklists and sample results as a
part of the quarterly program progress
report to the FDA Project officer or
designated office.
The grantee must file a final program
progress report, FSR, invention
VerDate jul<14>2003
18:11 Jun 30, 2005
Jkt 205001
statement, and disposition of equipment
statement within 90 days after the end
date of the project period as noted on
the notice of the cooperative agreement
award.
B. Monitoring Activities
The program project officer will
monitor grantees periodically. The
monitoring may be in the form of
telephone conversations, e-mails or
written correspondence between the
project officer/grants management
officer and the principal investigator.
Periodic site visits with officials of the
grantee organization may also occur.
The results of these monitoring
activities will be recorded in the official
cooperative agreement file and will be
available to the grantee upon request
consistent with applicable disclosure
statutes and FDA disclosure regulations.
The grantee organization must comply
with all special terms and conditions of
the cooperative agreement, including
those that state that future funding of
the study will depend on
recommendations from the project
officer. The scope of the
recommendation will confirm that: (1)
There has been acceptable progress on
the project; (2) there is continued
compliance with all FDA regulatory
requirements; (3) if necessary, there is
an indication that corrective action has
taken place; and (4) assurance that any
replacement of personnel will meet the
testing and inspection requirements.
VII. Agency Contacts
For issues regarding the
administrative and financial
management aspects of this notice:
Cynthia Polit (see section IV.1 of this
document).
For issues regarding the programmatic
or technical aspects of this notice: Neal
Bataller, Center for Veterinary Medicine,
Division of Compliance, Office of
Surveillance and Compliance (HFV–
235), Food and Drug Administration,
7500 Standish Pl., rm. E441, Rockville,
MD 20855, 240–276–9202, e-mail:
Neal.Bataller@fda.gov or Steve Toigo,
Division of Federal-State Relations
(HFC–150), Office of Regulatory Affairs,
Food and Drug Administration, 5600
Fishers Lane, rm. 12–07, Rockville, MD
20857, 301–827–6906, e-mail:
steve.toigo@fda.gov or access the
Internet at https://www.fda.gov/ora/
fed_state/default.htm.
VIII. Other Information
Data included in the application, if
restricted with the legend specified
below, may be entitled to confidential
treatment as trade secret or confidential
commercial information within the
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
meaning of the Freedom of Information
Act (5 U.S.C. 552(b)(4)) and FDA’s
implementing regulations (21 CFR
20.61).
Unless disclosure is required under
the Freedom of Information Act as
amended (5 U.S.C. 552) as determined
by the freedom of information officials
of the Department of Health and Human
Services, by a court, or required by
another Federal law, data contained in
the portions of this application that
have been specifically identified by
page number, paragraph, etc. by the
applicant as containing restricted
information, shall not be used or
disclosed except for evaluation
purposes.
Dated: June 27, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–13114 Filed 6–29–05; 9:03 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Blood Products Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Blood Products
Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on July 21, 2005, from 8 a.m. to
6:30 p.m.
Location: Holiday Inn Gaithersburg,
Two Montgomery Village Ave.,
Gaithersburg, MD.
Contact Person: William Freas or
Pearline K. Muckelvene, Center for
Biologics Evaluation and Research
(HFM–71), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852, 301–827–0314, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington, DC area), code
3014519516. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: On July 21, 2005, in the
morning, the committee will hear
updates on the following topics: (1)
E:\FR\FM\01JYN1.SGM
01JYN1
Agencies
[Federal Register Volume 70, Number 126 (Friday, July 1, 2005)]
[Notices]
[Pages 38177-38182]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-13114]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Ruminant Feed Ban Support Project; Availability of Cooperative
Agreements: Request for Applications: RFA-FDA-ORA-05-3; Catalog of
Federal Domestic Assistance Number: 93.449
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
I. Funding Opportunity Description
The Food and Drug Administration (FDA), Office of Regulatory
Affairs (ORA), Division of Federal-State Relations (DFSR) in
coordination with the Center for Veterinary Medicine (CVM), is
announcing the availability of cooperative agreements to further
enhance the infrastructure of State, territorial, and tribal animal
feed safety and bovine spongiform encephalopathy (BSE) prevention
programs. These cooperative agreements are intended to fund additional
personnel, equipment, supplies and training to support activities
related to the FDA ruminant feed ban (21 CFR part 589.2000) (referred
to as the ruminant feed ban), in State, territory, and tribal
governments.
Under these cooperative agreements, the State, territory, and
tribal governments would enhance their feed/BSE safety programs to
increase the ability to locate and visit firms involved in the
manufacture, distribution, and transportation of animal feed and
operations feeding ruminant animals in their jurisdiction, to verify
compliance with the ruminant feed ban. Funds could be used to increase
State, territory, and tribal personnel dedicated to conducting these
inspections. Funds could also be used for supplies, training, and
laboratory equipment for feed sample testing using FDA validated
methods. The goal of enhancing their feed/BSE safety programs is to
increase State, territory, and tribal inspections under section 702 of
the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 372)
of renderers, protein blenders, and feed mills that manufacture animal
feeds and feed ingredients, and inspections of salvagers of food and
feed, and transporters of animal feed and feed ingredients utilizing
materials prohibited under the ruminant feed ban. Finally, the Feed Ban
Support Project funds are intended to supplement, not replace, State
funding for program improvement.
[[Page 38178]]
There are seven key project areas identified for this effort:
Hire and/or train State/territory/tribal personnel to
conduct ruminant feed ban inspections. Training of State/territory/
tribal personnel may be accomplished through the ORA University, or the
Association of American Feed Control Officials Annual Feed Seminar, or
other training that meets State/territory/tribal and FDA requirements.
New hires for this program must meet the State/territory/tribal
agency's qualifications for feed inspections and sampling techniques.
Hire and/or train laboratory personnel to verify that feed
samples are free of materials prohibited under the ruminant feed ban.
Laboratory analyses must utilize FDA methodologies for detection of
prohibited materials.
Identify and inspect renderers, protein blenders,
commercial animal feed manufacturers, distributors (including
retailers), transporters of animal feed and feed ingredients, on-farm
animal feed mixers, and ruminant feeders within the State/territory/
tribal jurisdiction. These inspections would be conducted under section
702 of the FD&C Act using and completing the FDA Ruminant Feed Ban
Inspection Checklist and Ruminant Feed Ban Compliance Program to verify
compliance with the ruminant feed ban. These inspections would be
conducted by officers and employees duly commissioned by FDA in
accordance with section 702 of the FD&C Act.
Conduct surveillance sampling of renderers, protein
blenders, and feed mills that manufacture with materials prohibited
under the ruminant feed ban. A minimum of one sample from each facility
would be obtained during the inspection and would be analyzed by the
State/territorial/tribal government for prohibited materials. This
surveillance sampling would be conducted under section 702 of the FD&C
Act using and completing the FDA Ruminant Feed Ban Inspection Checklist
and Ruminant Feed Ban Compliance Program to verify compliance with the
ruminant feed ban. This surveillance sampling would be conducted by
officers and employees duly commissioned by FDA in accordance with
section 702 of the FD&C Act.
Locate and inspect other firms of specified concern, such
as feed salvagers, feed transporters, and ruminant feeders. These
inspections would be conducted under section 702 of the FD&C Act using
and completing the FDA Ruminant Feed Ban Inspection Checklist and
Ruminant Feed Ban Compliance Program to verify compliance with the
ruminant feed ban. These inspections would be conducted by officers and
employees duly commissioned by FDA in accordance with section 702 of
the FD&C Act.
Provide copies of all completed BSE checklists and sample
results as a part of the quarterly program progress report to the FDA
Project officer or designated office, as well as provide completed
checklists and sample results in accordance with section 702 of the
FD&C Act.
Be able to identify and quantify improvements to the
existing State/territory/tribal BSE program or developing new programs
(i.e., personnel hiring, personnel training, equipment upgrades,
increase in inspections conducted) in the quarterly reports as a result
of the cooperative agreement.
FDA will support the projects covered by this notice under the
authority of Section 311 of the Public Health Security and Bioterrorism
Preparedness and Response Act of 2002 (the Bioterrorism Act) (Public
Law 107-188), which amends the FD&C Act by adding section 909 (21
U.S.C. 399). FDA's research program is described in the Catalog of
Federal Domestic Assistance, No. 93.449.
1. Background
The events of September 11, 2001, reinforced the need to enhance
the security and safety of the U.S. food supply. Congress responded by
passing the Bioterrorism Act which President Bush signed into law on
June 12, 2002. The Bioterrorism Act is divided into the following five
titles:
Title I--National Preparedness for Bioterrorism and Other
Public Health Emergencies
Title II--Enhancing Controls on Dangerous Biological
Agents and Toxins
Title III--Protecting Safety and Security of Food and Drug
Supply
Title IV--Drinking Water Security and Safety
Title V--Additional Provisions
Subtitle A of Title III--Protection of Food Supply, Section 311--
Grants to States for Inspections, amends the FD&C Act by adding section
909 to authorize the Secretary of Health and Human Services to award
grants to States, territories, and Indian tribes that undertake
examinations, inspections, and investigations, and related activities
under section 702 of the FD&C Act. The grant funds are only available
for the costs of conducting these examinations, inspections,
investigations, and related activities.
Toward these ends, ORA is offering these cooperative agreements to
State/territorial/tribal governments for them to develop new or enhance
the capability of their existing Feed/BSE programs and assist in an
increased surveillance presence throughout the commercial feed channels
to prevent the introduction or amplification of BSE in the United
States. State/territorial/tribal inspections are based on a
determination of compliance of firms with the ``Animal Proteins
Prohibited In Ruminant Feeds'' regulation, (21 CFR 589.2000), as well
as any subsequent regulations and guidance applicable to the BSE
ruminant feed ban. This regulation is designed to prevent the
establishment and amplification of BSE through animal feed, by
prohibiting the use of certain proteins derived from mammalian tissue
in the feeding of ruminant animals. The regulation affects renderers,
protein blenders, commercial animal feed manufacturers, distributors
(including retailers), transporters of animal feed and feed
ingredients, on-farm animal feed mixers, and ruminant feeders. Based on
the need to control the entry and spread of this disease, the agency
has set a goal to assist in the development of new or the enhancement
of existing State/territory/tribal BSE programs to help meet compliance
with the regulation.
2. Program Goals
The goal of FDA's ORA Cooperative Agreement Program is to enhance,
complement, develop and improve State/territory/tribal feed safety and
surveillance programs. This will be accomplished through the provision
of funding for additional equipment, supplies, funding for personnel,
training in current FDA approved feed testing methodologies,
participation in proficiency testing to establish additional reliable
laboratory sample analysis capacity, and analysis of surveillance
samples and State/territorial/tribal compliance inspections. This will
also require extensive cooperation and coordination with FDA District
Offices to minimize duplication of inspections.
II. Award Information
1. Award Instrument
Support will be in the form of a cooperative agreement. Substantive
involvement by the awarding agency is inherent in the cooperative
agreement award. Accordingly, FDA will have substantial involvement in
the program activities of the project funded by the cooperative
agreement.
Substantive involvement includes, but is not limited to, the
following:
[[Page 38179]]
FDA assistance and coordination in the sharing of
information on the identification and location of all renderers,
protein blenders, commercial animal feed manufacturers, distributors
(including retailers), transporters of animal feed and feed
ingredients, on-farm animal feed mixers, and ruminant feeders known to
FDA and the State/territorial/tribal agency.
FDA assistance in the training of State/territorial/tribal
BSE program personnel.
FDA assistance in the training of State/territorial/tribal
laboratory personnel to verify that feed samples are free of materials
prohibited under the ruminant feed ban.
FDA assistance in the surveillance sampling of renderers,
protein blenders, and feed mills that manufacture with materials
prohibited under the ruminant feed ban.
FDA assistance and cooperation in the location and
inspection of other firms of specified concern, such as feed salvagers,
feed transporters, and ruminant feeders.
FDA will assist in the review of all completed checklists
and sample results provided as a part of the quarterly reports.
FDA will assist with joint inspections for training,
compliance, auditing or other field activities as requested by the
awardee.
2. Applicability
All cooperative agreement projects that are developed at State,
territorial, and tribal levels must have existing BSE feed safety and
surveillance programs or propose in detail the development of a State/
territory/tribal feed/BSE regulatory program.
3. Award Amount
The total amount of funding available in Fiscal Year (FY) 2005 is
$2 million. Cooperative agreements will be awarded up to $250,000 in
total (direct plus indirect) costs per year for up to three (3) years
and can be modified for years 2 and 3, depending on the availability of
funds and review of prior year's accomplishments.
4. Length of Support
The length of support will depend on the nature of the project. For
those projects with an expected duration of more than 1 year, a second
or third year of noncompetitive continuation of support will depend on
the following factors: (1) Performance during the preceding year and
(2) availability of Federal funds.
5. Funding Plan
It is anticipated that FDA will make up to ten awards in FY 2005.
The number of projects funded will depend on the quality of the
applications received and is subject to availability of Federal funds
to support the projects.
In addition, if a cooperative agreement is awarded, grantees will
be informed if any additional documentation should be needed to support
their award. Funds may be requested in the budget to travel to FDA for
meetings with program staff about the progress of the project. The
project office will have continuous interaction with the grantee
through inspection field audits, collection of quarterly progress
reports, and provision of training, joint inspections, and compliance.
There may be other regular meetings with grantees to assist in
fulfilling the requirements of the cooperative agreement.
These cooperative agreements will be made to either fund the
development of new State/territory/tribal BSE programs or to enhance
existing State/territory/tribal BSE programs for the funding of items
such as: Supplies, lab equipment, surveillance, sample collection,
personnel, for the provision of training in current inspectional and
analytical methodology, for the analysis of feed and feed products, and
ruminant feed ban inspections. Successful applications will be selected
for funding to ensure a broad geographic distribution of the program.
Size of the existing or new State/territory/tribal program and number
of facilities to be covered under the cooperative agreement will also
be a determining factor.
States with current BSE/ruminant feed ban contracts from FDA can
maintain these contracts for feed/BSE inspections at the discretion of
the State and FDA. However, the facilities and work covered under the
contract cannot be counted towards fulfillment of the cooperative
agreement and must remain distinct and separate from the cooperative
agreement. These cooperative agreements are not to fund licensed
medicated feed or routine feed safety good manufacturing practice (GMP)
inspections that are unrelated to the ruminant feed ban.
III. Eligibility Information
1. Eligible Applicants
This cooperative agreement program is only available to State,
territory, and tribal agency feed/BSE regulatory programs that
undertake inspections and related activities under section 702 of the
FD&C Act.
2. Cost Sharing or Matching
Cost sharing is not required.
3. Other
Dun and Bradstreet Number (DUNS).
As of October 1, 2003, applicants are required to have a DUNS
number to apply for a grant or cooperative agreement from the Federal
Government. The DUNS number is a 9-digit identification number that
uniquely identifies business entities. Obtaining a DUNS number is easy
and there is no charge. To obtain a DUNS number, call 1-866-705-5711.
Be certain that you identify yourself as a Federal grant applicant when
you contact Dun and Bradstreet.
IV. Application and Submission
1. Addresses to Request Application
FDA is accepting new applications for this program electronically
via Grants.gov. Applicants are strongly encouraged to apply
electronically by visiting the Web site https://www.grants.gov and
following instructions under ``APPLY.'' The required application PHS
424, which is part of the PHS 5161-1 form, can be completed and
submitted online. The package should be labeled ``Response to RFA-FDA-
ORA-05-3.'' If you experience technical difficulties with your online
submission you should contact either Cynthia Polit, Grants Management
Specialist, Division of Contracts and Grants Management (HFA-500), Food
and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-
827-7180, e-mail: cpolit@oc.fda.gov or the Grants.gov Customer Response
Center for assistance.
To comply with the President's Management Agenda, the Department of
Health and Human Services is participating as a partner in the new
governmentwide Grants.gov Apply site. Users of Grants.gov will be able
to download a copy of the application package, complete it offline, and
then upload and submit the application via the Grants.gov site. We
request your participation in the Grants.gov project. When you enter
the Grants.gov site, you will find information about submitting an
application electronically through the site.
In order to apply electronically, the applicant must have a DUNS
number and register in the Central Contractor Registration (CCR)
database as described in section IV.6.A of this document.
[[Page 38180]]
2. Content and Form of Application
A. General Information
The applicant will be judged on, and must specifically address, the
following in the cooperative agreement application:
Demonstrate the availability of adequately trained BSE
program staff and/or the criteria to hire and/or train personnel to
conduct ruminant feed ban inspections.
Demonstrate the availability of adequately trained
laboratory personnel and the criteria to hire and/or train laboratory
personnel to verify that feed samples are free of materials prohibited
under the ruminant feed ban. Verify that laboratory analyses will
utilize FDA approved tests and methodologies for detection of
prohibited materials.
Provide a detailed description of current feed regulatory
program or proposal to develop a feed regulatory program, including
types of inspections performed, and types and numbers of feed
establishments in the State/territorial/tribal inventory.
Provide a properly detailed budget that is intended to
develop or enhance the BSE program in the State/territory/tribe.
Provide an accurate count of all feed facilities including
renderers, protein blenders, commercial animal feed manufacturers,
distributors (including retailers), transporters of animal feed and
feed ingredients, on-farm animal feed mixers, and ruminant feeders in
their State, territory, or tribal government. Provide an indication of
how many of each of these facilities would be covered each year under
this agreement.
Provide a detailed description of how the BSE program
inspections and/or feed sampling and analyses are to be performed.
Provide detailed descriptions on how current, noninspected
facilities and/or nonidentified facilities will be identified and added
to the State's inspection responsibilities.
Demonstrate the ability to satisfy the reporting
requirements outlined in section VI.3.A of this notice.
Provide current funding level certification for their
existing BSE program from State/territory/tribal funding
appropriations.
Outline detailed methodology for program improvement or
program development to accomplish the work.
Provide justification for hiring new staff, hiring
qualifications, their training needs and any new equipment.
Provide a clearly detailed description how the State/
territory/tribe BSE program will follow the procedures set forth in
section 702 of the FD&C Act for notifying FDA of violative facilities
for enforcement under FDA jurisdiction.
B. Laboratory Facilities
The applicant must provide a complete description of the
facilities, including the following information: The name and address
of the State/territory/tribal facility conducting the BSE testing; the
name of the most responsible individual for the facility where the
testing will be conducted; and, the location and installation
requirements of any equipment purchased with cooperative agreement
funds.
Other facilities information that must be provided includes:
Operational support areas to be used for the project,
including details about the availability of ancillary laboratory safety
and support equipment and facilities;
Details describing the sample receiving and sample storage
areas and a description of any existing chain-of-custody procedures;
A detailed description of the proposed upgrades to
existing laboratory facilities to accommodate new equipment including
drawings and cost estimates.
Laboratory Management Practices:
For the laboratory, the following management information must be
provided:
A summary description of any quality management system
defined, in development, or in place as it relates to quality control
and quality assurance procedures and practices;
A summary description of staffing management, specifically
to include BSE testing abilities and procedures;
A summary description of procedures in place to monitor
BSE sample workflow, including the tracking and monitoring of sample
analyses in progress to include a description of the laboratory work
product review process. Additionally, the ability to perform and
complete the BSE analyses and provide a report of a sample analysis
within a responsive and reasonable timeframe must be described. At a
minimum, the grantee shall utilize and follow the laboratory testing
procedures, methodology, and protocol employed and approved by FDA in
the testing of all BSE samples to ensure compliance with the ruminant
feed ban.
In addition, if a cooperative agreement is awarded, grantees will
be informed if any additional documentation should be needed to support
their award.
C. Format for Application
Data and information included in the application will generally not
be publicly available prior to the funding of the application. After
funding has been granted, data and information included in the
application will be given confidential treatment to the extent
permitted by the Freedom of Information Act (5 U.S.C. 552(b)(4)) and
FDA's implementing regulations (including 21 CFR 20.61, 20.105, and
20.106). By accepting funding, the applicant agrees to allow FDA to
publish specific information about the cooperative agreement.
Information collection requirements requested on Form PHS 5161-1
(Rev. 7/00) have been sent by PHS to the Office of Management and
Budget (OMB) and have been approved and assigned OMB control number
0348-0043.
3. Submission Dates and Times
For FY 05, the application receipt date is August 15, 2005.
Applications will be accepted from 8 a.m. to 4:30 p.m., Monday
through Friday, until the established receipt date. Please do not send
applications to the Center for Scientific Review (CSR) at the National
Institutes of Health (NIH). Any application sent to NIH/CSR that is
forwarded to the FDA Grants Management Office and not received in time
for orderly processing will be judged nonresponsive and returned to the
applicant.
Applications submitted electronically must be received by the close
of business on the established receipt date.
No addendum material will be accepted after the established receipt
date.
4. Intergovernmental Review
The regulations issued under Executive Order 12372,
Intergovernmental Review of Federal Programs (45 CFR part 100) apply.
Applicants (other than federally recognized Indian Tribal governments)
should contact the State's Single Point of Contact (SPOC) as early as
possible to alert the SPOC to the prospective application(s) and to
receive any necessary instructions on the State's review process. A
current listing of SPOCs is located at: http//www.whitehouse.gov/omb/
grants/spoc.htlm. The SPOC should send any State review process
recommendations to the FDA administrative contact (see Agency Contacts
in section VII of this document). The due date for the State process
recommendations is no later than 60 days after the deadline date for
the receipt of applications. FDA does
[[Page 38181]]
not guarantee to accommodate or explain SPOC comments that are received
after the 60-day cutoff.
5. Funding Restrictions
These cooperative agreements are not to fund licensed medicated
feed or routine feed safety GMP inspections that are unrelated to the
ruminant feed ban. These awards may be only used for the development of
new State/territory/tribal BSE programs or to enhance and supplement
existing State/territory/tribal BSE program funding. States with
current BSE/ruminant feed ban contracts from FDA can maintain these
contracts for feed/BSE inspections at the discretion of the State and
FDA. However, the facilities and work covered under the contract cannot
be counted towards fulfillment of the cooperative agreement and must
remain distinct and separate from the cooperative agreement.
6. Other Submission Requirements
A. Central Contractor Registration
In anticipation of the https://www.grants.gov electronic application
process, applicants must register with the CCR database. This database
is a governmentwide warehouse of commercial and financial information
for all organizations conducting business with the Federal Government.
Registration with CCR will eventually become a requirement and is
consistent with the governmentwide management reform to create a
citizen-centered web presence and build e-gov infrastructures in and
across agencies to establish a ``single face to industry.'' The
preferred method for completing a registration is through the World
Wide Web at https://www.ccr.gov. This Web site provides a CCR handbook
with detailed information on data you will need prior to beginning the
online pre-registration, as well as steps to walk you through the
registration process. You must have a DUNS number to begin your
registration.
In order to access https://grants.gov an applicant will be required
to register with the Credential Provider. Information about this is
available at https://www.grant.gov/CredentialProvider.
B. Copyright Material
Applicants and applicants' sub-grantees and sub-contractors must
ensure compliance that any projects developed in whole or in part with
Federal funds may be made available to other State, territorial, local,
and tribal feed/BSE regulatory agencies by FDA or its agents. Any
copyrighted or copyrightable works shall be subject to a royalty-free,
nonexclusive, and irrevocable license to the Federal Government to
reproduce, publish, or otherwise use them, and to authorize others to
do so for Federal Government purposes.
V. Application Review Information
1. Criteria
A. General Information
FDA grants management and program staff will review all
applications sent in response to this notice. To be responsive, an
application must be submitted in accordance with the requirements of
this notice and must bear the original signature of the applicant
institution's/organization's authorized official. Applications found to
be nonresponsive will be returned to the applicant without further
consideration. Applicants are strongly encouraged to contact FDA to
resolve any questions about criteria before submitting their
application. Please direct all questions of a technical or scientific
nature to the ORA program staff and all questions of an administrative
or financial nature to the grants management staff (see Agency Contacts
in section VII of this document).
The original signature requirement does not apply to applications
submitted electronically.
B. Scientific/Technical Review Criteria
Applications will be considered for funding on the basis of their
overall technical merit as determined through the review process.
Program criteria will include availability of funds and overall program
balance in terms of geography and with respect to existing inventory of
feed firms within their State.
The ad hoc expert panel will review applications based on the
``Content and Form of Application'' requirements listed in section
IV.2.A of this document.
A score will be assigned based on the scientific/technical review
criteria. The review panel may advise the program staff about the
appropriateness of the proposal to the goals of this ORA/Office of
Regional Operations (ORO)/DFSR and CVM cooperative agreement program.
C. Program Review Criteria
Applications will be considered for funding on the basis of their
overall technical merit as determined through the review process.
Program criteria will include availability of funds and overall program
balance in terms of geography with respect to existing and projected
awards.
2. Review and Selection Process
Responsive applications will be reviewed and evaluated for
scientific and technical merit by an ad hoc panel of experts in the
subject field of the specific application. Final funding decisions will
be made by the Commissioner of Food and Drugs or his designee.
3. Anticipated Announcement and Award
Notification regarding the results of the review is anticipated by
September 1, 2005. The expected start date for the FY 05 awards will be
September 29, 2005.
VI. Award Administration Information
1. Award Notices
The FDA Grants Management Office will notify applicants who have
been selected for an award. Awards will either be issued on a Notice of
Grant Award (PHS 5152) signed by the FDA Chief Grants Management
Officer and be sent to successful applicants by mail or be transmitted
electronically.
2. Administrative and National Policy Requirements
These agreements will be subject to all applicable policies and
requirements that govern the grant programs of PHS, including 45 CFR
part 92 and the PHS Grants Policy Statement.
Equipment purchased under this cooperative agreement is subject to
the requirements of 45 CFR part 92.31, ``Real property.''
Applicants must adhere to the requirements of this Notice. Special
Terms and Conditions regarding FDA regulatory requirements and adequate
progress of the study may be part of the awards notice.
PHS strongly encourages all cooperative agreement recipients to
provide a smoke-free workplace and to discourage the use of all tobacco
products. This is consistent with the PHS mission to protect and
advance the physical and mental health of the American people.
FDA is committed to achieving the health promotion and disease
prevention objectives of ``Healthy People 2010,'' a national effort
designed to reduce morbidity and mortality and to improve quality of
life. Applicants may obtain a paper copy of the ``Healthy People 2010''
objectives, vols. I and II, for $70 ($87.50 foreign) S/N 017-000-00550-
9, by writing to the Superintendent of Documents, P.O. Box 371954,
Pittsburgh, PA 15250-7954. Telephone orders can be placed to 202-512-
2250. The document is also
[[Page 38182]]
available in CD-ROM format, S/N 017-001-00549-5 for $19 ($23.50
foreign) as well as on the Internet at https://www.healthypeople.gov/.
(FDA has verified the Web site address, but we are not responsible for
subsequent changes to the Web site after this document publishes in the
Federal Register.) Internet viewers should proceed to ``Publications.''
3. Reporting
A. Reporting Requirements
The original and two copies of the annual Financial Status Report
(FSR) (SF-269) must be sent to FDA's grants management officer within
90 days of the budget period end date of the grant. For continuing
cooperative agreements, an annual program progress report is also
required. For such cooperative agreements, the noncompeting
continuation application (PHS 5161-1) will be considered the annual
program progress report.
Quarterly progress reports as well as a final program progress
report are required. Quarterly progress reports must contain, but are
not limited to the following:
1. Status report on the installation and operational readiness of
any analytical equipment that is purchased.
2. Status report on the hiring and training of State/territorial/
tribal laboratory personnel.
3. Copies of the inspection report on the firms for which Ruminant
Feed Ban Inspection checklists were completed including general
assessment of compliance status.
4. Summary report on the facility inventory that is maintained in
the State/territory/tribal government.
5. Status report on the hiring and training of personnel to conduct
the inspections.
6. Report on feed sample descriptions and subsequent analytical
results.
7. Where the examinations, inspections, or investigations and
related activities undertaken under section 702 of the FD&C Act result
in a State/territorial/tribal enforcement action, a summary report of
the followup actions and final resolution of the findings.
8. Summary of improvements (identify and quantify) in the overall
State/territory/tribal BSE program resulting from the cooperative
agreement.
9. Provide copies of all completed BSE checklists and sample
results as a part of the quarterly program progress report to the FDA
Project officer or designated office.
The grantee must file a final program progress report, FSR,
invention statement, and disposition of equipment statement within 90
days after the end date of the project period as noted on the notice of
the cooperative agreement award.
B. Monitoring Activities
The program project officer will monitor grantees periodically. The
monitoring may be in the form of telephone conversations, e-mails or
written correspondence between the project officer/grants management
officer and the principal investigator. Periodic site visits with
officials of the grantee organization may also occur. The results of
these monitoring activities will be recorded in the official
cooperative agreement file and will be available to the grantee upon
request consistent with applicable disclosure statutes and FDA
disclosure regulations. The grantee organization must comply with all
special terms and conditions of the cooperative agreement, including
those that state that future funding of the study will depend on
recommendations from the project officer. The scope of the
recommendation will confirm that: (1) There has been acceptable
progress on the project; (2) there is continued compliance with all FDA
regulatory requirements; (3) if necessary, there is an indication that
corrective action has taken place; and (4) assurance that any
replacement of personnel will meet the testing and inspection
requirements.
VII. Agency Contacts
For issues regarding the administrative and financial management
aspects of this notice: Cynthia Polit (see section IV.1 of this
document).
For issues regarding the programmatic or technical aspects of this
notice: Neal Bataller, Center for Veterinary Medicine, Division of
Compliance, Office of Surveillance and Compliance (HFV-235), Food and
Drug Administration, 7500 Standish Pl., rm. E441, Rockville, MD 20855,
240-276-9202, e-mail: Neal.Bataller@fda.gov or Steve Toigo, Division of
Federal-State Relations (HFC-150), Office of Regulatory Affairs, Food
and Drug Administration, 5600 Fishers Lane, rm. 12-07, Rockville, MD
20857, 301-827-6906, e-mail: steve.toigo@fda.gov or access the Internet
at https://www.fda.gov/ora/fed_state/default.htm.
VIII. Other Information
Data included in the application, if restricted with the legend
specified below, may be entitled to confidential treatment as trade
secret or confidential commercial information within the meaning of the
Freedom of Information Act (5 U.S.C. 552(b)(4)) and FDA's implementing
regulations (21 CFR 20.61).
Unless disclosure is required under the Freedom of Information Act
as amended (5 U.S.C. 552) as determined by the freedom of information
officials of the Department of Health and Human Services, by a court,
or required by another Federal law, data contained in the portions of
this application that have been specifically identified by page number,
paragraph, etc. by the applicant as containing restricted information,
shall not be used or disclosed except for evaluation purposes.
Dated: June 27, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-13114 Filed 6-29-05; 9:03 am]
BILLING CODE 4160-01-S